Bevacizumab Plus Atezolizumab After Progression on Atezolizumab Monotherapy in Pretreated Patients With NSCLC: An Open-Label, Two-Stage, Phase 2 Trial-Reference-Cited by-同舟云学术

Bevacizumab Plus Atezolizumab After Progression on Atezolizumab Monotherapy in Pretreated Patients With NSCLC: An Open-Label, Two-Stage, Phase 2 Trial

Published:2022-07 Issue:7 Volume:17 Page:900-908
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Lee Jiyun,Koh Jiae,Kim Hee Kyung,Hong Sungsoo,Kim Kyunga,Park Sehhoon,Jung Hyun Ae,Sun Jong-Mu,Lee Se-Hoon,Ahn Jin Seok,Park Keunchil,Ahn Myung-Ju

Funder

Roche

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference23 articles.

1. Immunotherapy for non-small cell lung cancer: current landscape and future perspectives;Lim;Immune Netw,2020

2. Current state of immunotherapy for non-small cell lung cancer;Malhotra;Transl Lung Cancer Res,2017

3. The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC;Manegold;J Thorac Oncol,2017

4. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa;Khan;Nat Rev Clin Oncol,2018

5. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity;Lee;Exp Mol Med,2020

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): a single-arm, phase II study;European Journal of Cancer;2024-09

2. Advancing non-small cell lung cancer treatment: the power of combination immunotherapies;Frontiers in Immunology;2024-07-02

3. Safety and efficacy of multi-target TKI combined with nivolumab in check-point inhibitor-refractory patients with advanced NSCLC: a prospective, single-arm, two-stage study;BMC Cancer;2024-06-11

4. Endothelial cells in tumor microenvironment: insights and perspectives;Frontiers in Immunology;2024-02-15

5. Effectiveness of PD1/PD-L1 combined with anti-angiogenic drugs in patients with advanced nonsmall cell lung cancer: A systematic review and meta-analysis;Journal of Research in Medical Sciences;2024-02